Genialis™ Supermodel: Predicting monotherapy and combination therapy responses in KRAS-mutated cancers using a large molecular model of cancer biology
KRAS mutations drive approximately 25% of human cancers, resulting [...]
Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123
The WEE1 kinase is a central regulator of G2/M [...]
Highlights from Fireside Chat with Rafael Rosengarten
"In cancer treatment, a simple yes or no isn’t [...]
Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM podcast #44
Genialis’ Upcoming Events Genialis on LinkedIn [...]
Data-driven cancer care: Luka Ausec on the Faces of Digital Health podcast
Genialis’ Chief Discovery Officer, Luka Ausec, recently joined Tjaša [...]
Reinventing diagnostics: The superpower of not knowing what can’t be done | TPM podcast #43
Genialis extends its collaboration with Debiopharm [...]
Rafael Rosengarten shares his biotech journey on The Biotech Startups Podcast
Rafael Rosengarten, CEO of Genialis, recently joined The Biotech [...]
The journey to the top of life sciences technology: a lifetime of listening and learning | TPM podcast #42
Tempus Announces a Collaboration With Genialis [...]
Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways
Extending their collaboration, Genialis and Debiopharm continue working towards [...]
Genialis’ biomarkers recognized for innovation in precision oncology
2024 has been an exciting year for Genialis as [...]
